Dr Reinhard Malin

Hydra Biosciences and Boehringer Ingelheim enter research collaboration to identify small-molecule TRP inhibitors for the treatment of renal diseases and disorders

CAMBRIDGE, Massachusetts and INGELHEIM, Germany, 14-4-2015 — /EuropaWire/ — Hydra Biosciences, Inc., a leader in the field of transient receptor potential (TRP)…

9 years ago

950 treatment naïve genotype-1b patients enrolled for two of Boehringer Ingelheim pivotal Phase III interferon-free hepatitis C clinical trials

Over 950 patients have now been successfully enrolled in the pivotal Phase III HCVerso™1 and 2 trials The Phase III…

11 years ago